Tofacitinib onveiliger dan TNF-α-remmer bij reumatoïde artritis

Sofia Ramiro; Robert Landewé; D. sirée van der Heijde

Tofacitinib onveiliger dan TNF-α-remmer bij reumatoïde artritis

Translated title of the contribution: What do the results of the ORAL surveillance study mean for the treatment of rheumatoid arthritis with tofacitinib?

Sofia Ramiro, Robert Landewé, D. sirée van der Heijde

Research output: Contribution to journal › Article › Professional

Abstract

Tofacitinib is a relatively new oral drug for the treatment of rheumatoid arthritis. The ORAL surveillance study shows in a direct comparison that more patients with RA develop a 'major adverse cardiovascular event' (MACE) or malignancy during treatment with tofacitinib than during treatment with a tumor necrosis factor (TNF) inhibitor. The reliability of the study, the generalisability and interpretation of the results, as well as their implication for daily practice are discussed here.

Translated title of the contribution	What do the results of the ORAL surveillance study mean for the treatment of rheumatoid arthritis with tofacitinib?
Original language	Dutch
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	166
Publication status	Published - 9 Jun 2022

Cite this

@article{271df9801f374453b7acf9210eb89369,

title = "Tofacitinib onveiliger dan TNF-α-remmer bij reumato{\"i}de artritis",

abstract = "Tofacitinib is a relatively new oral drug for the treatment of rheumatoid arthritis. The ORAL surveillance study shows in a direct comparison that more patients with RA develop a 'major adverse cardiovascular event' (MACE) or malignancy during treatment with tofacitinib than during treatment with a tumor necrosis factor (TNF) inhibitor. The reliability of the study, the generalisability and interpretation of the results, as well as their implication for daily practice are discussed here.",

author = "Sofia Ramiro and Robert Landew{\'e} and {van der Heijde}, {D. sir{\'e}e}",

year = "2022",

month = jun,

day = "9",

language = "Dutch",

volume = "166",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

}

TY - JOUR

T1 - Tofacitinib onveiliger dan TNF-α-remmer bij reumatoïde artritis

AU - Ramiro, Sofia

AU - Landewé, Robert

AU - van der Heijde, D. sirée

PY - 2022/6/9

Y1 - 2022/6/9

N2 - Tofacitinib is a relatively new oral drug for the treatment of rheumatoid arthritis. The ORAL surveillance study shows in a direct comparison that more patients with RA develop a 'major adverse cardiovascular event' (MACE) or malignancy during treatment with tofacitinib than during treatment with a tumor necrosis factor (TNF) inhibitor. The reliability of the study, the generalisability and interpretation of the results, as well as their implication for daily practice are discussed here.

AB - Tofacitinib is a relatively new oral drug for the treatment of rheumatoid arthritis. The ORAL surveillance study shows in a direct comparison that more patients with RA develop a 'major adverse cardiovascular event' (MACE) or malignancy during treatment with tofacitinib than during treatment with a tumor necrosis factor (TNF) inhibitor. The reliability of the study, the generalisability and interpretation of the results, as well as their implication for daily practice are discussed here.

UR - http://www.scopus.com/inward/record.url?scp=85135202931&partnerID=8YFLogxK

M3 - Article

C2 - 35899714

SN - 0028-2162

VL - 166

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

ER -

Tofacitinib onveiliger dan TNF-α-remmer bij reumatoïde artritis

Abstract

Other files and links

Cite this